Related Experiment Video

Updated: May 30, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status

Nina Tiemann1, Guido Hildebrandt, Katrin Manda

  • 1Department of Radiotherapy and Radiation Oncology, University of Rostock, Südring 75, 18059 Rostock, Germany.

Medical Oncology (Northwood, London, England)
|August 16, 2011
PubMed

Insights

Panitumumab showed cytotoxic effects and enhanced radiosensitivity in KRAS-mutated cancer cells, but not in wild-type cells. This suggests other factors beyond KRAS status influence Panitumumab

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Panitumumab, a fully human monoclonal antibody, targets the epidermal growth factor receptor (EGFR).
  • Current clinical use of Panitumumab is restricted to patients with a non-mutated KRAS status.
  • The influence of KRAS status on Panitumumab's efficacy requires further investigation.

Purpose of the Study:

  • To investigate the in vitro cytotoxic and radiosensitizing effects of Panitumumab.
  • To determine if KRAS mutational status influences Panitumumab's efficacy.
  • To assess Panitumumab's impact on DNA damage and repair.

Main Methods:

  • In vitro study using KRAS wild-type (HT-29) and KRAS mutant (A549) cancer cell lines.
  • Cell proliferation and cytotoxicity assays (BrdU, LDH release).
  • Colony-forming assays and γH2AX foci assay to assess radiosensitivity and DNA damage.

Main Results:

  • Panitumumab exhibited concentration-independent growth inhibition and cytotoxicity exclusively in the KRAS-mutated A549 cell line.
  • Panitumumab enhanced the radiosensitivity of A549 cells when combined with irradiation.
  • No significant effects of Panitumumab on cell growth, LDH release, or survival were observed in KRAS wild-type HT-29 cells.

Conclusions:

  • KRAS mutational status plays a role in Panitumumab's cytotoxic and radiosensitizing efficacy.
  • The response to Panitumumab may be influenced by factors other than KRAS status.
  • Further research is needed to elucidate the regulatory mechanisms governing Panitumumab response.

More Related Videos

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...